På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

11 Oct 2011

OncoNOx completes seed financing

OncoNOx ApS and SEED Capital today announced the formation and seed funding of a novel cancer company OncoNOx ApS. The company has developed a series of novel anti-cancer compounds, which are modifications of already approved drugs. The compounds are more potent than standard cancer chemotherapeutics in several animal models of cancer.

OncoNOx is founded by a very experienced group of scientists and biotech executives from Italy, Switzerland, USA and Denmark. Headed by Professor Ferdinando Nicoletti (Chief Scientific Officer of OncoNOx) the international group has discovered and characterized novel cancer compounds for the past 6 years.

OncoNOx has two compounds in preclinical testing for cancer: OX1001 (Saq-NO), which is an analog of the marketed protease inhibitor Saquinavir and OX27-NO, a derivative of an anti-inflammatory compound in clinical development.

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2011 Danskbiotek. All rights reserved.